Program
Cytarabine
Also written as “cytarabine”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Cytarabine (Ara-C)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia · Lymphoma · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Mesothelioma, Malignant, led by 23 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 30 open or running | phase 3since Oct 4, 2000 | Oct 4, 2000 | none ahead |
| Vion Pharmaceuticals | 30 open or running | phase 2since Jul 19, 2006 | Jul 8, 2003 | none ahead |
| Antisoma Research | 20 open or running | phase 3since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 2since Mar 4, 2008 | Mar 4, 2008 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 2since Aug 16, 2007 | Aug 16, 2007 | none ahead |
| Moleculin Biotech | 21 open or running | phase 3since Dec 5, 2024 | Feb 22, 2022 | Aug 2029phase 3 · NCT06788756 |
| Theradex | 20 open or running | phase 2since Oct 3, 2003 | Jan 27, 2003 | none ahead |
| AbbVie | 10 open or running | phase 3since Aug 10, 2020 | Aug 10, 2020 | none ahead |
| arog-pharmaceuticals-inc | 10 open or running | phase 2since Oct 18, 2017 | Oct 18, 2017 | none ahead |
| cornerstone-pharmaceuticals | 10 open or running | phase 3since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| CSPC Pharmaceutical Group | 10 open or running | phase 2since Oct 19, 2021 | Oct 19, 2021 | none ahead |
| eleos-inc | 10 open or running | phase 2since Dec 19, 2003 | Dec 19, 2003 | none ahead |
| kanisa-pharmaceuticals | 10 open or running | phase 2since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Kura Oncology | 11 open or running | phase 3since May 16, 2025 | May 16, 2025 | Nov 2031phase 3 · NCT07007312 |
| oncovir-inc | 10 open or running | phase 1since Aug 19, 2020 | Aug 19, 2020 | none ahead |
| Pfizer | 10 open or running | phase 3since Dec 21, 2017 | Dec 21, 2017 | none ahead |
| polaris-group | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Sichuan Biokin Pharmaceutical | 11 open or running | phase 3since Nov 20, 2025 | Nov 20, 2025 | Dec 2027phase 3 · NCT07255872 |
| Stelexis BioSciences | 11 open or running | phase 1since Jul 24, 2024 | Jul 24, 2024 | Dec 15, 2027phase 1 · NCT06533761 |
| Sumitomo Pharma | 10 open or running | phase 1since Sep 27, 2017 | Sep 27, 2017 | none ahead |
| tarapeutics-science-inc | 11 open or running | phase 2since Jan 16, 2022 | Jan 16, 2022 | none ahead |
| texas-oncology-cancer-center | 10 open or running | phase 2since Nov 18, 2011 | Nov 18, 2011 | none ahead |
| xanthus-pharmaceuticals-inc | 10 open or running | phase 2since Jan 5, 2006 | Jan 5, 2006 | none ahead |
Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Oct 4, 2000.
- Aug 9, 2016polaris-group's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to polaris-grouppolaris-group · NCT02875093 · 23 enrolled · Taiwan
- Sep 27, 2017Sumitomo Pharma's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Sumitomo PharmaSumitomo Pharma · NCT03298984 · 32 enrolled · United States
- Oct 18, 2017arog-pharmaceuticals-inc's first study: phase 2 study in RecurrenceNew to arog-pharmaceuticals-incarog-pharmaceuticals-inc · NCT03324243
- Dec 21, 2017Pfizer's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to PfizerPfizer · NCT03416179 · 730 enrolled · United States, Australia, Austria and more
- Apr 12, 2018cornerstone-pharmaceuticals's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to cornerstone-pharmaceuticalscornerstone-pharmaceuticals · NCT03504410 · 200 enrolled · United States, Australia, Austria and more
- Aug 10, 2020AbbVie's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT04509622 · 14 enrolled · Japan
- Aug 19, 2020oncovir-inc's first study: phase 1 study in Mesothelioma, MalignantNew to oncovir-inconcovir-inc · NCT04525859 · 19 enrolled · United States
- Oct 19, 2021CSPC Pharmaceutical Group's first study: phase 2 study in RecurrenceNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05100303 · 58 enrolled · China
- Jan 16, 2022tarapeutics-science-inc's first study: phase 2 study in RecurrenceNew to tarapeutics-science-inctarapeutics-science-inc · NCT05241093 · 18 planned · China
- Feb 22, 2022Moleculin Biotech's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Moleculin BiotechMoleculin Biotech · NCT05319587 · 22 enrolled · Italy, Poland
- Jul 24, 2024Stelexis BioSciences's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Stelexis BioSciencesStelexis BioSciences · NCT06533761 · 105 planned · United States, Spain
- Dec 5, 2024Phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756 · 312 planned · United States, Czechia, Georgia and more
- May 16, 2025Kura Oncology's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
- Nov 20, 2025Sichuan Biokin Pharmaceutical's first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07255872 · 216 planned · China
Ahead
- Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteSichuan Biokin Pharmaceutical · NCT07255872
- Dec 15, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteStelexis BioSciences · NCT06533761
- Aug 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756
- Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07255872Leukemia, Myeloid, Acute · China | 3 | Recruiting | Sichuan Biokin Pharmaceutical | Dec 2027 | 216 |
| NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more | 3 | Recruiting | Kura Oncology | Nov 2031 | 1,300 |
| NCT06788756Leukemia, Myeloid, Acute · United States, Czechia, Georgia and more | 3 | Recruiting | Moleculin Biotech | Aug 2029 | 312 |
| NCT06533761Leukemia, Myeloid, Acute · United States, Spain | 1 | Recruiting | Stelexis BioSciences | Dec 15, 2027 | 105 |
| NCT05319587Leukemia, Myeloid, Acute · Italy, Poland | 2 | Completed | Moleculin Biotech | Aug 2, 2023 | 22 |
| NCT05241093Recurrence · China | 2 | Recruiting | tarapeutics-science-inc | Dec 30, 2025 | 18 |
| NCT05100303Recurrence · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Nov 2022 | 58 |
| NCT04525859Mesothelioma, Malignant · United States | 1 | Completed | oncovir-inc | Jun 18, 2025 | 19 |
| NCT04509622Leukemia, Myeloid, Acute · Japan | 3 | Completed | AbbVie | Apr 15, 2021 | 14 |
| NCT03504410Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Terminated | cornerstone-pharmaceuticals | Oct 25, 2021 | 200 |
| NCT03416179Leukemia, Myeloid, Acute · United States, Australia, Austria and more | 3 | Completed | Pfizer | Jun 5, 2020 | 730 |
| NCT03324243Recurrence | 2 | Withdrawn | arog-pharmaceuticals-inc | Dec 2020 | 0 |
| NCT03298984Leukemia, Myeloid, Acute · United States | 1 | Completed | Sumitomo Pharma | Mar 20, 2020 | 32 |
| NCT02875093Leukemia, Myeloid, Acute · Taiwan | 1 | Terminated | polaris-group | Jul 10, 2019 | 23 |
| NCT01773408Leukemia, Myeloid, Acute · United States, Australia, Canada and more | 1 | Completed | Hoffmann-La Roche | Jun 2016 | 122 |
| NCT01500161Leukemia, Myeloid, Acute · United States | 2 | Terminated | texas-oncology-cancer-center | Nov 2013 | 1 |
| NCT01066494Leukemia, Myeloid, Acute · Georgia, Ukraine | 2 | UNKNOWN | Antisoma Research | Sep 2010 | 20 |
| NCT00804856Leukemia, Myeloid, Acute · Austria, Belgium, Canada and more | 2 | Completed | Boehringer Ingelheim | Mar 9, 2012 | 180 |
| NCT00715637Leukemia · United States, Argentina, Australia and more | 3 | UNKNOWN | Antisoma Research | Jun 2010 | 420 |
| NCT00632749Leukemia, Myeloid, Acute · Germany | 2 | Completed | Boehringer Ingelheim | Mar 2014 | 68 |
| NCT00517699Lymphoma · Canada | 2 | Terminated | Hoffmann-La Roche | Mar 2009 | 5 |
| NCT00354276Leukemia · United States, France, United Kingdom | 2 | UNKNOWN | Vion Pharmaceuticals | Dec 2008 | 85 |
| NCT00333840Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more | 3 | Completed | Novartis | Mar 2012 | 1,106 |
| NCT00273884Leukemia, Myeloid, Acute · United States, Canada | 2 | Completed | xanthus-pharmaceuticals-inc | 80 | |
| NCT00129168Leukemia, Myeloid | 2 | Completed | kanisa-pharmaceuticals | Mar 2008 | 100 |
| NCT00093600Leukemia, Myeloid, Acute · United States, Germany | 1 | Completed | Novartis | Jun 2011 | 69 |
| NCT00074737Leukemia, Myeloid, Acute · United States | 2 | Completed | eleos-inc | May 2007 | 53 |
| NCT00070538Leukemia · United States | 1 | Completed | Vion Pharmaceuticals | Sep 2004 | |
| NCT00069966Lymphoma · United States, Puerto Rico | 2 | UNKNOWN | Theradex | ||
| NCT00064090Leukemia · United States | 1 | Completed | Vion Pharmaceuticals | Sep 2004 | |
| NCT00053105Lymphoma · United States | 1 | UNKNOWN | Theradex | ||
| NCT00006343Leukemia · United States | 3 | Completed | Novartis | Mar 2007 |
How it is read
Names in the registry
- “Cytarabine”, 15 entries
- “cytarabine”, 8 entries
- “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
- “Cytarabine (Ara-C)”, 1 entry
- “Eganelisib in combination with cytarabine”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 22 studies
- Leukemia, 3 studies
- Lymphoma, 2 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
- Mesothelioma, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.